Scholars Central

Review articlePublished 10 Jan 2019

The Progressive Journey from Ductal Carcinoma in situ into Invasive Breast Cancer: An Extensive Systematic Literature Review on Biomarkers

Authors: Ercilia Da Gloria LI, Jian-Xin Lv, Guy-Armel Bounda, Xin-Hua Cao, Hao-Lin Hu, Ya-Nan Zhang (China)

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Breast Cancer (BC) is the most common cancer in women, and second most cancer worldwide. It is a progressive and fatal disease that affects women of all ages, and is divided into several subtypes with distinct histological, genomic and transcriptomic profiles, outcomes, and responses to therapy. Ductal carcinoma in situ (DCIS) is a pre-invasive stage in the development of invasive breast carcinoma. DCIS presents a clinical problem, with high risk of potential progressive disease. A subset of patients with ductal carcinoma in situ (DCIS) will develop Invasive Breast Cancer (IBC). Thus, biomarkers are pivotal important to help identify DCIS/ IBC genes that might probably lead to potential rational treatment therapies. While biomarkers are defined as indicators of normal biological processes, pathogenic processes, or pharmacologic responses to therapeutic intervention, cancer biomarkers provide diagnostic, prognostic and therapeutic information about a particular cancer and show their ever-increasing importance in early detection and diagnosis of the disease. Estrogen Receptor (ER), Progesterone Receptor (PR), antigen KI-67 (Ki67), Her2, and cytokeratin’s are among the approved biomarkers by the Food and Drug Administration (FDA) for disease diagnosis, prognosis, and therapy selection. Up to now, little is known/or there is still a lot to know about molecular biomarkers (BM) that may help to determine the likelihood that DCIS identified on diagnostic biopsy would remain contained in situ or become invasive. This review elaborates and emphasizes on biomarkers that have the potential to identify cancer progression, and it enlightens research in breast cancer biomarkers related to DCIS and IBC.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Oncology: Case Reports
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Ercilia Da Gloria LI”
  • BylineArticles whose byline prints “Jian-Xin Lv”
  • BylineArticles whose byline prints “Guy-Armel Bounda”
  • BylineArticles whose byline prints “Xin-Hua Cao”
  • BylineArticles whose byline prints “Hao-Lin Hu”
  • BylineArticles whose byline prints “Ya-Nan Zhang (China)”